Vaxart

Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded in 2004 and is headquartered in South San Francisco, CA.

Earnings data Q2 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded in 2004 and is headquartered in South San Francisco, CA.

GT Biopharma Inc

Novan

Ocugen, Inc.

Are these former penny stocks on your watch list right now? The post 4 Penny Stocks To Watch Hit It Big In 2021, 1 Up Over 2,200% Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Penny Stocks To Watch Hit It Big In 2021, 1 Up Over 2,200% Right Now

Smartsheet

Twilio

Zoom Video

PlayAGS

Air Products and Chemicals

Celsius Holdings

Nasdaq

Vertex Pharmaceuticals

With the trading day about halfway over, the markets were sliding lower to close out the week.

Nasdaq, Smartsheet, Twilio, Vaxart, Zoom Video and More Friday Afternoon Analyst Calls

This isn't the first time its coronavirus vaccine pill has disappointed investors.

Why Shares of Vaxart Plummeted 38.6% in May

Reimagining Covid-19 vaccines isn't an easy task, but Vaxart is prepared to innovate - and VXRT stock could move higher at any given moment. The post Bet on a No-Needle Vaccine Strategy with Vaxart appeared first on InvestorPlace.

Bet on a No-Needle Vaccine Strategy with Vaxart

Magnite

Plug Power

Teladoc

If analysts are correct, this assortment of rapidly growing companies could deliver big-time returns over the next year.

5 High-Octane Growth Stocks With 54% to 94% Upside, According to Wall Street

Inovio Pharmaceuticals

Moderna

Novavax

Pfizer

These Vaccine Latecomers Could Still Win Big. Here's How

SOUTH SAN FRANCISCO, Calif., June 07, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that its executive officers, Andrei Floroiu, CEO, and Sean Tucker, CSO, are scheduled to present at the SVB Leerink CybeRx Series: Vaccine Forum on Monday, June 21, 2021 at 1:00 p.m. Eastern Time.

Vaxart to Present at the SVB Leerink CybeRx Series: Vaccine Forum

As a company attempting to make oral vaccines, Vaxart has a compelling story. However VXRT stock looks to be many years away from paying off.

Vaxart's Compelling Story Will Take a Long Time to Play Out

Prior to the vaccination rollout from Vaxart's competitors, VXRT stock appeared a compelling alternative. That's no longer the case.

With Fading Covid-19 Infections, Vaxart's Relevance Is Waning

SOUTH SAN FRANCISCO, Calif., May 27, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that Andrei Floroiu, CEO and Sean Tucker, CSO of the Vaxart executive team are scheduled to present at the Jefferies Virtual Healthcare Conference on Friday, June 4, 2021 at 1:30 p.m. Eastern Time.

Vaxart to Present at the Jefferies Virtual Healthcare Conference

Vaxart's vaccine pill could prove to be effective against the original Covid-19 virus and its new variants, sending VXRT stock sky-high. The post Speculators Should Consider Buying Vaxart Stock appeared first on InvestorPlace.

Speculators Should Consider Buying Vaxart Stock

Ardelyx

PDS Biotechnology Corporation

Penny stocks that left the nest in 2021 To Watch Right Now The post Small-Cap & Penny Stocks To Watch In May Hitting It Big In 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Small-Cap & Penny Stocks To Watch In May Hitting It Big In 2021

VXRT Stock needs to nail the next few studies of its Covid 19 vaccine candidate and prove its thesis to widen its bull case significantly The post Vaxart Could Still Be a Viable Covid 19 Vaccine Play appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now It doesn't matter if you have $500 in savings or $5 million.

Vaxart Could Still Be a Viable Covid 19 Vaccine Play

These two high-flying biotechs are vying for the same market.

Ocugen or Vaxart: Which Will Take Investors Further?

Vaxart stock is likely headed down 85% towards its cash per share. VXRT stock is not worth much more than $1.00 per share, so expect to see it drop 85%.

High Cash Burn Will Push Vaxart Stock Down To $1 Per Share

This is a risky play, with a catalyst that more likely than not won't pan out. But, if it releases more promising news within the coming months, it could go on yet another parabolic run.

It Won't Take Much for Vaxart Stock to Pop Once Again

Investors need to pay close attention to Vaxart (VXRT) stock based on the movements in the options market lately.

Do Options Traders Know Something About Vaxart (VXRT) Stock We Don't?

Can this troubled coronavirus vaccine developer redeem itself and its investors?

Is Vaxart a Buy?

VXRT stock is down from its highs, but there's no need to worry, as Vaxart has a unique Covid-19 vaccine and some encouraging clinical data. The post Vaxart's No-Shot Vaccine Is a Potential Game Changer appeared first on InvestorPlace.

Vaxart's No-Shot Vaccine Is a Potential Game Changer

As with most investment decisions, whether to hold depends on the situation. Here are some things to think about.

Is Vaccine Maker Vaxart Worth Holding From Here?

Study will evaluate safety and immunogenicity of oral norovirus vaccine in elderly population

Vaxart Announces First Subject Enrolled in Phase 1b Norovirus Dose-Ranging Trial in Elderly Adults

Here's how the biotechs compare on several key fronts.

Better Vaccine Stock: Ocugen or Vaxart?

If it can reach the market of people that are hesitant to be vaccinated, yes.

Vaxart's Vaccine Candidate Is a Pill, Not a Shot. Does It Matter?

Its coronavirus vaccine candidate may stand out, if upcoming trials are successful.

Vaxart Has 3 Advantages Over Pfizer and Moderna

Investors are excited about the company's experimental COVID-19 vaccine.

News for Vaxart Stock (VXRT)